Consistent with the role of HA in promoting tumor growth and metastasis [49], mice implanted with HAS3-luc transfectant developed visible kidney tumors within three weeks and mRCC in < 5 weeks (Fig. 9A, B). The gene discussed is HAS3; the disease is neoplasm.